{
  "url": "https://openlegislation.uk/russia-sanctions-eu-exit-regulations-2019/schedule-2A/paragraph-9",
  "json_url": "https://openlegislation.uk/russia-sanctions-eu-exit-regulations-2019/schedule-2A/paragraph-9.json",
  "legislation": "uksi/2019/855",
  "legislation_title": "The Russia (Sanctions) (EU Exit) Regulations 2019",
  "legislation_url": "https://openlegislation.uk/russia-sanctions-eu-exit-regulations-2019",
  "path": "schedule/2A/paragraph/9",
  "kind": "paragraph",
  "number": "9",
  "heading": null,
  "text": "Energetic materials as follows and mixtures thereof, except where the material is incorporated in a medical product—\n(a) ammonium picrate (CAS 131-74-8);\n(b) black powder;\n(c) hexanitrodiphenylamine (CAS 131-73-7);\n(d) difluoroamine (CAS 10405-27-3);\n(e) nitrostarch (CAS 9056-38-6);\n(f) tetranitronaphthalene;\n(g) trinitroanisole;\n(h) trinitronaphthalene;\n(i) trinitroxylene;\n(j) N-pyrrolidinone; 1-methyl-2-pyrrolidinone (CAS 872-50-4);\n(k) dioctylmaleate (CAS 142-16-5);\n(l) ethylhexylacrylate (CAS 103-11-7);\n(m) triethylaluminium (TEA) (CAS 97-93-8), trimethylaluminium (TMA) (CAS 75-24-1), and other pyrophoric metal alkyls and aryls of lithium, sodium, magnesium, zinc or boron;\n(n) nitroglycerin (or glyceroltrinitrate, trinitroglycerine) (NG) (CAS 55-63-0);\n(o) Ethylenediaminedinitrate (EDDN) (CAS 20829-66-7);\n(p) lead azide (CAS 13424-46-9), normal lead styphnate (CAS 15245-44-0) and basic lead styphnate (CAS 12403-82-6), and primary explosives or priming compositions containing azides or azide complexes;\n(q) diethyldiphenylurea (CAS 85-98-3); dimethyldiphenylurea (CAS 611-92-7); methylethyldiphenyl urea;\n(r) N,N-diphenylurea (unsymmetrical diphenylurea) (CAS 603-54-3);\n(s) methyl-N,N-diphenylurea (methyl unsymmetrical diphenylurea) (CAS 13114-72-2);\n(t) ethyl-N,N-diphenylurea (ethyl unsymmetrical diphenylurea) (CAS 64544-71-4);\n(u) 4-Nitrodiphenylamine (4-NDPA)(CAS 836-30-6);\n(v) 2,2-dinitropropanol (CAS 918-52-5).\nNote: For the purpose of this entry, “medical product” means (1) a pharmaceutical formulation designed for human administration in the treatment of medical conditions, and (2) prepackaged for distribution as a clinical or medical product.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Sch. 2A Pt. 9 inserted (16.12.2022) by The Russia (Sanctions) (EU Exit) (Amendment) (No. 17) Regulations 2022 (S.I. 2022/1331), reg. 1(2)(b), Sch. 1 Pt. 2"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2019/855/schedule/2A/paragraph/9",
    "retrieved_at": "2026-10-28T22:41:25.449074+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}